focus -WSS

focus

author：fashion 2025-09-06 03:52:58 - browse：6

U.S. legislation that would sever ties with Chinese drugmakers would jeopardize the drug supply for millions of American patients if it’s passed, the biotechnology industry’s main trade group has told Congress.

Congress is considering legislation, called the BIOSECURE Act, that would make it difficult for Chinese contract development and manufacturing organizations to do business with biotechnology companies that work with the U.S. federal government. Biotechs hire Chinese CDMOs, as they’re often called, for services that include product manufacturing, development, formulation, packaging, and distribution.

The BIOSECURE Act would stop the federal government from contracting with, or providing grants to, companies that do business with so-called Chinese “companies of concern.” The impact of the legislation would depend in large part on who is in the White House. The White House’s Office of Management and Budget would determine which companies are blacklisted, but a handful of specific companies would automatically go on that list, including the biotech giant WuXi AppTec.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Liquid biopsy for lung cancer is launched by Delfi

WSS

The United States must get value

As H5N1 spreads in cows, experts warn against drinking raw milk

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

WuXi Biologics beefs up its lobbying operation

Cherokee Nation medical school graduates its first class

Supreme Court to hear if Covid misinformation is protected speech

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Wikipedia

Guidelines to prevent youth baseball injuries need more muscle

Ripples from Flovent's discontinuation is killing children with asthma

Heart attack and stroke risk calculators need revising

WuXi Biologics execs register to lobby as Congress comes for the company

Trump demands the U.S. pay no more for drugs than other countries … again

HHS suspends federal funding for EcoHealth Alliance

Supreme Court strikes down use of affirmative action

FDA panel signals lack of confidence in Amgen cancer drug data

The high cost of giving birth even with insurance

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

entertainment

Bristol 'take

Hottest summer in 2,000 years puts focus on extreme heat, health

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Lilly’s weekly insulin works as well as daily products, new studies show

Analysis of telehealth claims data suggest service duplication

What a koala virus tells us about the human genome

entertainment

hotspot

focus

entertainment